Oosterwijk E - Search Results

1

Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.

Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Liu Z, et al. Among authors: oosterwijk e. Cancer Immunol Immunother. 2002 May;51(3):171-7. doi: 10.1007/s00262-002-0268-4. Epub 2002 Mar 1. Cancer Immunol Immunother. 2002. PMID: 11941456 Free PMC article.

2

Immunization with anti-idiotype monoclonal antibodies bearing the internal image of the renal-cell carcinoma-associated antigen G250 induces specific cellular immune responses.

Uemura H, Okajima E, Debruyne FM, Oosterwijk E. Uemura H, et al. Among authors: oosterwijk e. Int J Cancer. 1994 Dec 15;59(6):802-7. doi: 10.1002/ijc.2910590616. Int J Cancer. 1994. PMID: 7989122

3

Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.

van Dijk J, Uemura H, Beniers AJ, Peelen WP, Zegveld ST, Fleuren GJ, Warnaar SO, Oosterwijk E. van Dijk J, et al. Among authors: oosterwijk e. Int J Cancer. 1994 Jan 15;56(2):262-8. doi: 10.1002/ijc.2910560220. Int J Cancer. 1994. PMID: 8314310

4

Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, et al. Oosterwijk E, et al. J Clin Oncol. 1993 Apr;11(4):738-50. doi: 10.1200/JCO.1993.11.4.738. J Clin Oncol. 1993. PMID: 8478666 Clinical Trial.

5

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.

Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM. Surfus JE, et al. Among authors: oosterwijk e. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):184-91. doi: 10.1097/00002371-199605000-00003. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8811493

6

Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.

Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ. Divgi CR, et al. Among authors: oosterwijk e. Clin Cancer Res. 1998 Nov;4(11):2729-39. Clin Cancer Res. 1998. PMID: 9829736 Clinical Trial.

7

Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.

Steffens MG, Boerman OC, Oyen WJ, Kniest PH, Witjes JA, Oosterhof GO, van Leenders GJ, Debruyne FM, Corstens FH, Oosterwijk E. Steffens MG, et al. Among authors: oosterwijk e. Cancer Res. 1999 Apr 1;59(7):1615-9. Cancer Res. 1999. PMID: 10197637

8

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J. Bleumer I, et al. Among authors: oosterwijk e. Br J Cancer. 2004 Mar 8;90(5):985-90. doi: 10.1038/sj.bjc.6601617. Br J Cancer. 2004. PMID: 14997194 Free PMC article. Clinical Trial.

9

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.

Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Völler MC, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PF. Bleumer I, et al. Among authors: oosterwijk e, oosterwijk wakka jc. J Urol. 2006 Jan;175(1):57-62. doi: 10.1016/S0022-5347(05)00040-6. J Urol. 2006. PMID: 16406869 Clinical Trial.

10

Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.

Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wüest T, Stenner F, Perani A, Cohen L, Knuth A, Divgi C, Jäger D, Scott AM, Ritter G, Old LJ, Renner C. Bauer S, et al. Among authors: oosterwijk e, oosterwijk wakka jc. Int J Cancer. 2009 Jul 1;125(1):115-23. doi: 10.1002/ijc.24359. Int J Cancer. 2009. PMID: 19384924

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters